Zhejiang Hisun Pharmaceutical's Subsidiary Obtains Veterinary Drug Approval

Stock News12-05

Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Yunnan Biological Pharmaceutical Co., Ltd. (referred to as "Yunnan Biological"), a subsidiary under Zhejiang Hisun Animal Health Products Co., Ltd., recently received approval from the Ministry of Agriculture and Rural Affairs of China for the veterinary drug product license of the Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain).

The Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain) is indicated for the prevention of swine mycoplasma pneumonia (swine enzootic pneumonia). Immunity develops 28 days after vaccination, with a protection period of six months. The vaccine is produced by inoculating Mycoplasma hyopneumoniae strain GD0503 in MH medium, followed by concentration, purification, inactivation, and formulation with an oil adjuvant.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107076839?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107076839","market":"us","top_or_hot":-1,"title":"Zhejiang Hisun Pharmaceutical's Subsidiary Obtains Veterinary Drug Approval","media":"Stock News","content":"<p>Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Yunnan Biological Pharmaceutical Co., Ltd. (referred to as \"Yunnan Biological\"), a subsidiary under Zhejiang Hisun Animal Health Products Co., Ltd., recently received approval from the Ministry of Agriculture and Rural Affairs of China for the veterinary drug product license of the Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain).</p>\n<p>The Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain) is indicated for the prevention of swine mycoplasma pneumonia (swine enzootic pneumonia). Immunity develops 28 days after vaccination, with a protection period of six months. The vaccine is produced by inoculating Mycoplasma hyopneumoniae strain GD0503 in MH medium, followed by concentration, purification, inactivation, and formulation with an oil adjuvant.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Hisun Pharmaceutical's Subsidiary Obtains Veterinary Drug Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Hisun Pharmaceutical's Subsidiary Obtains Veterinary Drug Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-05 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Yunnan Biological Pharmaceutical Co., Ltd. (referred to as \"Yunnan Biological\"), a subsidiary under Zhejiang Hisun Animal Health Products Co., Ltd., recently received approval from the Ministry of Agriculture and Rural Affairs of China for the veterinary drug product license of the Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain).</p>\n<p>The Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain) is indicated for the prevention of swine mycoplasma pneumonia (swine enzootic pneumonia). Immunity develops 28 days after vaccination, with a protection period of six months. The vaccine is produced by inoculating Mycoplasma hyopneumoniae strain GD0503 in MH medium, followed by concentration, purification, inactivation, and formulation with an oil adjuvant.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600267","symbol_name":"海正药业","start_time":0,"source_url":"","article_id":"1107076839","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107076839","pubTimestamp":1764924149,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Yunnan Biological Pharmaceutical Co., Ltd. (referred to as \"Yunnan Biological\"), a subsidiary under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"浙江海正药业子公司获兽药批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":1},"content_text":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Yunnan Biological Pharmaceutical Co., Ltd. (referred to as \"Yunnan Biological\"), a subsidiary under Zhejiang Hisun Animal Health Products Co., Ltd., recently received approval from the Ministry of Agriculture and Rural Affairs of China for the veterinary drug product license of the Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain).\nThe Swine Mycoplasma Hyopneumoniae Inactivated Vaccine (GD0503 strain) is indicated for the prevention of swine mycoplasma pneumonia (swine enzootic pneumonia). Immunity develops 28 days after vaccination, with a protection period of six months. The vaccine is produced by inoculating Mycoplasma hyopneumoniae strain GD0503 in MH medium, followed by concentration, purification, inactivation, and formulation with an oil adjuvant.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107076839","isCrawlerRequest":true}